Pharmacokinetics of 6-Gingerol, 8-Gingerol, 10-Gingerol, and 6-Shogaol and Conjugate Metabolites in Healthy Human Subjects
-
- Suzanna M. Zick
- 1Family Medicine, Departments of
-
- Zora Djuric
- 1Family Medicine, Departments of
-
- Mack T. Ruffin
- 1Family Medicine, Departments of
-
- Amie J. Litzinger
- 1Family Medicine, Departments of
-
- Daniel P. Normolle
- 2Radiation Oncology, and
-
- Sara Alrawi
- 1Family Medicine, Departments of
-
- Meihua Rose Feng
- 4College of Pharmacy and Engineering, University of Michigan Medical School, Ann Arbor, Michigan
-
- Dean E. Brenner
- 3Internal Medicine; and
書誌事項
- 公開日
- 2008-08-01
- DOI
-
- 10.1158/1055-9965.epi-07-2934
- 公開者
- American Association for Cancer Research (AACR)
この論文をさがす
説明
<jats:title>Abstract</jats:title> <jats:p>Background: Ginger shows promising anticancer properties. No research has examined the pharmacokinetics of the ginger constituents 6-gingerol, 8-gingerol, 10-gingerol, and 6-shogaol in humans. We conducted a clinical trial with 6-gingerol, 8-gingerol, 10-gingerol, and 6-shogaol, examining the pharmacokinetics and tolerability of these analytes and their conjugate metabolites.</jats:p> <jats:p>Methods: Human volunteers were given ginger at doses from 100 mg to 2.0 g (N = 27), and blood samples were obtained at 15 minutes to 72 hours after a single p.o. dose. The participants were allocated in a dose-escalation manner starting with 100 mg. There was a total of three participants at each dose except for 1.0 g (N = 6) and 2.0 g (N = 9).</jats:p> <jats:p>Results: No participant had detectable free 6-gingerol, 8-gingerol, 10-gingerol, or 6-shogaol, but 6-gingerol, 8-gingerol, 10-gingerol, and 6-shogaol glucuronides were detected. The 6-gingerol sulfate conjugate was detected above the 1.0-g dose, but there were no detectable 10-gingerol or 6-shogaol sulfates except for one participant with detectable 8-gingerol sulfate. The Cmax and area under the curve values (mean ± SE) estimated for the 2.0-g dose are 0.85 ± 0.43, 0.23 ± 0.16, 0.53 ± 0.40, and 0.15 ± 0.12 μg/mL; and 65.6.33 ± 44.4, 18.1 ± 20.3, 50.1 ± 49.3, and 10.9 ± 13.0 μg·hr/mL for 6-gingerol, 8-gingerol, 10-gingerol, and 6-shogaol. The corresponding tmax values are 65.6 ± 44.4, 73.1 ± 29.4, 75.0 ± 27.8, and 65.6 ± 22.6 minutes, and the analytes had elimination half-lives <2 hours. The 8-gingerol, 10-gingerol, and 6-shogaol conjugates were present as either glucuronide or sulfate conjugates, not as mixed conjugates, although 6-gingerol and 10-gingerol were an exception.</jats:p> <jats:p>Conclusion: Six-gingerol, 8-gingerol, 10-gingerol, and 6-shogaol are absorbed after p.o. dosing and can be detected as glucuronide and sulfate conjugates. (Cancer Epidemiol Biomarkers Prev 2008;17(8):1930–6)</jats:p>
収録刊行物
-
- Cancer Epidemiology, Biomarkers & Prevention
-
Cancer Epidemiology, Biomarkers & Prevention 17 (8), 1930-1936, 2008-08-01
American Association for Cancer Research (AACR)
